-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

398 Addition of Monoclonal Protein to MALT-IPI Improved Identification of MALT Patients at High Risk of Progression with Current First-Line Therapies

Program: Oral and Poster Abstracts
Type: Oral
Session: 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Learning from the Real World: Predictors of Outcomes in Understudied Lymphomas and Underrepresented Populations
Hematology Disease Topics & Pathways:
Research, Clinical Research, Real-world evidence
Saturday, December 7, 2024: 4:15 PM

Narendranath Epperla, MD, MS1, Natalie Grover, MD2, Pallawi Torka, MD3, Reem Karmali, MD4, Kaitlin Annunzio, DO5, Marcus P. Watkins, PhD6*, Andrea Carolina Anampa-Guzmán, MD7*, Heather Reves, MS, BS8*, Montreh Tavakkoli, MD9, Beth Christian, MD10, Colin Thomas, MD11, Stefan K. Barta, MD12, Praveen Ramakrishnan Geethakumari, MD, MS8, Geoffrey Shouse, PhD, DO13, Nancy L. Bartlett, MD14 and Adam J. Olszewski, MD15

1Division of Hematology, Department of Medicine, The Ohio State University, The James Cancer Hospital and Solove Research Institute, Columbus, OH
2University of North Carolina, Chapel Hill, NC
3Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
4Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
5The James Cancer Center, The Ohio State University Wexner Medical Center, Columbus, OH
6Division of Oncology, Washington University School of Medicine, St. Louis, MO
7Roswell Park Comprehensive Cancer Center, Buffalo, NY
8Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX
9Department of Medicine, Division of Hematology/Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA
10Division of Hematology, The Ohio State University, Columbus, OH
11Department of Medicine, University of Pennsylvania, Philadelphia, PA
12Abramson Cancer Center, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA
13City of Hope Cancer Center, Duarte, CA
14Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO
15Brown University, Providence, RI

Introduction
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (EMZL or MALT lymphoma) is the most common subtype of MZL. MALT international prognostic index (IPI) was derived from the IELSG-19 trial wherein patients (pts) were randomized to rituximab (R), chlorambucil, or their combination. It identified age ≥70 years, stage 3/4, and an elevated lactate dehydrogenase (LDH) level as prognostic factors (Thieblemont C, Blood 2017). However, chlorambucil +/-R is rarely used in the first-line MZL treatment in USA, so the utility of MALT-IPI in pts receiving current standard immunochemotherapy is unclear. Furthermore, MALT-IPI did not include monoclonal protein (M-protein), which is an independent prognostic variable (Epperla N, Blood Adv 2023). Hence, we evaluated the outcomes of pts with MALT lymphoma treated in the contemporary era, using stratification by MALT-IPI with addition of M-protein.

Methods
This multicenter, retrospective cohort study included adult pts with MALT lymphoma diagnosed from 2010-2020, who had information on MALT-IPI at diagnosis, and who were treated at 10 US medical centers using first-line R monotherapy, R+bendamustine, RCHOP, or RCVP. Main endpoints were progression-free survival (PFS) and overall survival (OS) measured from the start of first-line therapy. Survival was estimated from flexible parametric models, reporting hazard ratios (HR) with 95% confidence intervals (CI). Missing data were accounted for using multiple imputation.

Results
The study included 468 pts (72% aged ≤70 years; 56% women; 42% stage 3/4), whose EMZL was treated with first-line R monotherapy (62%), R-bendamustine (29%), or RCHOP/RCVP (9%). MALT-IPI was low in 40%, intermediate (int) in 37%, and high in 23%.

The 5-year PFS for MALT-IPI low, int and high groups were 72%, 64%, and 48%, respectively. The difference between low and int groups was not statistically significant (HR=1.38; 95%CI 0.93-2.04; P=0.11). Based on observed outcomes for all subgroups, presence of M-protein provided additional prognostication for the high MALT-IPI group, but not for the groups with low/int MALT-IPI. Therefore, we defined a dichotomous EMZL-MPI defining “high risk” (15% of pts) as the group with MALT-IPI high and M-protein present, and EMZL-MPI “low risk” for all other combinations. The 5-year PFS was 39% and 67% for the two groups, respectively (HR=2.41; 95%CI, 1.61-3.61; P<0.0001). Thus, combining M-protein with MALT-IPI identified a subset of EMZL pts at risk for shorter PFS after current first-line therapies.

EMZL-MPI reclassified 35% of high MALT-IPI pts as low risk, and the 5-year PFS for the reclassified group did not significantly differ from the low/int MALT-IPI (65% vs 67%, HR=1.07, 95%CI 0.51-2.25; P=0.85).

The 5-year estimates for OS for MALT-IPI groups were 97% for low, 91% for int (HR=2.28; 95%CI 0.98-5.59; P=0.07), and 81% for high (HR=4.87; 95%CI, 2.00-11.8; P<.001). The estimates for low- and high-risk EMZL-MPI groups were 93% and 79%, respectively (HR=3.17; 95%CI, 1.50-6.70; P=0.002). Similar to PFS, we found that the 86% 5-year OS for the high MALT-IPI reclassified as low-risk EMZL-MPI was not statistically significantly different from the OS in the low/int MALT-IPI groups (P=0.23).

We further investigated whether the prognostic significance of the high-risk EMZL-MPI differs according to first-line therapy. High-risk EMZL-MPI was prognostic for shorter PFS after R monotherapy (HR=2.94; 95%CI 1.67-5.19; P=0.0002), whereas high MALT-IPI without M-protein was not (HR=1.07; 95%CI 0.39-2.96; P=0.89). Similar results were obtained for OS. In contrast, for pts treated with combination immunochemotherapy, neither high-risk EMZL-MPI (HR=1.00; 95%CI 0.40-2.53; P=0.99) nor high MALT-IPI (HR=0.88; 95%CI=0.31-2.55; P=0.82) were prognostic.

Discussion
In this multicenter study, the addition of M-protein to high MALT-IPI helped identify a truly high-risk subgroup (MALT-IPI high/M-protein present) of pts with EMZL, particularly those treated with anti-CD20 antibody alone. Measuring the presence of M-protein at diagnosis in all newly diagnosed pts may improve prognostication and influence the choice of therapy. Neither MALT-IPI nor EMZL-MPI provide sufficient prognostication for pts receiving combination immunochemotherapy, and novel prognostic biomarkers are needed for stratification in this setting.

Disclosures: Epperla: Novartis: Consultancy; Ispen: Other: Advisory Board; Lilly: Other: Advisory Board; Genetech: Speakers Bureau; Beigene: Speakers Bureau. Grover: Novartis: Honoraria; Regeneron: Honoraria, Research Funding; ADC Therapeutics: Honoraria; BMS: Honoraria, Research Funding; Caribou: Honoraria; Ono Pharma: Honoraria; Genentech: Honoraria; Cabaletta: Research Funding; Janssen: Honoraria; Kite: Honoraria; Sangamo: Current holder of stock options in a privately-held company; Seagen: Honoraria; Poseida: Research Funding. Torka: ADC Therapeutics: Consultancy; Abbvie: Consultancy; TG Therapeutics: Consultancy; Genmab: Consultancy; Genentech: Consultancy; Lilly Oncology: Consultancy; Seagen: Consultancy. Karmali: Ipsen: Speakers Bureau; BMS: Honoraria; Incyte: Speakers Bureau; AstraZeneca: Speakers Bureau; Abbvie: Honoraria; Genmab: Honoraria; BeiGene: Speakers Bureau; Genentech/Roche: Honoraria. Christian: Millenium: Research Funding; Genentech: Research Funding; Acerta: Research Funding; Astra Zeneca: Honoraria; Ipsen: Honoraria; Bristol Myers Squibb: Research Funding. Barta: Acrotech: Consultancy; Kyowa Kirin: Consultancy; Daiichi Sankyo: Consultancy; BMS: Consultancy; Janssen: Membership on an entity's Board of Directors or advisory committees. Ramakrishnan Geethakumari: Ipsen Biopharma: Membership on an entity's Board of Directors or advisory committees; Ono Pharma: Membership on an entity's Board of Directors or advisory committees; Cellectar Biosciences: Membership on an entity's Board of Directors or advisory committees; ADC therapeutics: Membership on an entity's Board of Directors or advisory committees; Kite Pharma: Consultancy; Bristol Myers Squibb: Consultancy; Regeneron Pharma: Membership on an entity's Board of Directors or advisory committees. Shouse: Abbvie: Consultancy; Beigene, Inc: Consultancy, Honoraria, Speakers Bureau; Astra Zeneca: Honoraria; Kite Pharmaceuticals: Consultancy, Honoraria, Speakers Bureau. Bartlett: BMS: Research Funding; Celegne: Research Funding; Autolus: Research Funding; AbbVie: Membership on an entity's Board of Directors or advisory committees; Gilead: Research Funding; ADC Therapeutics: Research Funding; Washington University School of Medicine: Current Employment; Janssen: Research Funding; Forty Seven: Research Funding; Millennium: Research Funding; Kite Pharm: Membership on an entity's Board of Directors or advisory committees, Research Funding; Roche/Genentech: Membership on an entity's Board of Directors or advisory committees, Research Funding; Pharmacyclics: Research Funding; Seattle Genetics: Research Funding; Pfizer: Membership on an entity's Board of Directors or advisory committees; Genmab: Membership on an entity's Board of Directors or advisory committees, Research Funding; Foresight Diagnostics: Membership on an entity's Board of Directors or advisory committees. Olszewski: Genmab, Schrodinger, ADC Therapeutics, BeiGene, Bristol-Myers Squibb: Consultancy; Genmab, Schrodinger, Genentech, Inc., Precision Biosciences, Artiva, Pfizer, Kymera Therapeutics: Research Funding.

*signifies non-member of ASH